Table 1 DNA (%) presented in “head” and “tail” pre- and post-incubation with doxorubicin in breast cancer cell lines
Control | Cisplatin (1 μM) | |||
|---|---|---|---|---|
% DNA | % DNA | % DNA | % DNA | |
(mean ± 1.96 S.E.) | (mean ± 1.96 S.E.) | (mean ± 1.96 S.E.) | (mean ± 1.96 S.E.) | |
in Head | in Tail | in Head | in Tail | |
LoVo | 83.55 ± 4.25 | 17.45 ± 4.12 | 89.28 ± 2.32 | 11.72 ± 2.29 |
HCT-15 | 78.58 ± 4.05 | 21.42 ± 4.05 | 92.35 ± 1.84 | 7.65 ± 1.83 |
HCT-116 | 84.92 ± 3.32 | 15.08 ± 3.27 | 92.50 ± 2.00 | 8.51 ± 1.88 |
HT55 | 82.17 ± 2.75 | 17.82 ± 2.75 | 90.60 ± 1.58 | 9.39 ± 1.51 |